MicroPort, No. 1601 Zhangdong Road, Shanghai (2026)

22/05/2026

As wraps up, we extend our heartfelt gratitude to everyone who visited the booth, joined our sessions, and connected with us throughout an inspiring week in Paris.

This year, we proudly showcased multiple innovative products debuting in France and presented a series of new clinical findings highlighting the growing strength of MicroPort’s portfolio. Each presentation reflected our continued commitment to advancing innovation and clinical evidence in .

Thank you for being part of this journey. We look forward to seeing you next year at !

18/05/2026

Bonjour, Paris!🇫🇷

We‘re thrilled to be back at . Looking forward to exchanging ideas, sharing insights, and discovering new breakthroughs in together.

Visit us at Booth M8 — see you tomorrow!

TeleRoboticPCI MedTech

08/05/2026

🌍 Join at

📅 May 19-22, 2026
📍 Booth M8, Level 2, Palais des Congrès de Paris

Paris, we're back — with fresh momentum and new possibilities for hashtag .

This time, we're bringing:
• Cutting-edge innovations debuting in France
• Advanced and comprehensive hashtag solution portfolio
• Upcoming clinical evidence shaping the future of practice

Let's continue driving cardiovascular breakthroughs together. See you in Paris!🌟

07/04/2026

🌏 Join us at in Shanghai

📅 April 9-12, 2026
📍 Hall 5.1 M37
🏢 National Exhibition and Convention Center (Shanghai)

At the 93rd China International Medical Equipment Fair (CMEF), brings together 10 business segments under the theme "Intelligence Integration, Beyond Boundaries". We will showcase our latest advancements in AI-enabled diagnostics, intelligent surgical systems, and a full portfolio spanning cardiovascular, neurovascular, orthopedics, robotics, and beyond — demonstrating how we are building a connected ecosystem to redefine the future of healthcare.

Let's explore, connect, and inspire together.

27/02/2026

On February 27, announced that its First-in-Class ™ Piezoelectric Coronary CTO Crossing Guidewire has received official approval from the National Medical Products Administration ( ) of China through the Innovative Medical Device Special Review ("Green Channel") program.

🚀 Product Highlights:
The system converts electrical energy into precisely controlled high-frequency mechanical vibrations, transmitted along the guidewire shaft to its distal tip, enabling targeted antegrade mechanical impulses to facilitate CTO lesion pe*******on and micro-channel creation.

1️⃣ Enhanced Pe*******on of Complex CTO Lesions: Effectively addresses resistant fibrotic proximal caps and heavily calcified occlusions that may be refractory to conventional guidewires.

2️⃣ Improved Revascularization Success: Lesion-targeted mechanical energy delivery supports successful recanalization and restoration of coronary blood flow across a broader CTO patient population.

3️⃣ Reduced Procedural Risk and Optimized Efficiency: Controlled lesion crossing may reduce wire escalation, shorten procedure time, and lower potential intra-procedural risks, thereby enhancing overall treatment safety.

The approval of FireSpear™ marks a significant milestone in our commitment to advancing coronary artery disease treatment, showcasing our strong R&D capabilities and ability to translate cutting-edge engineering into clinically meaningful innovation. Looking ahead, we aim to enable more patients worldwide to live .

12/02/2026

As comes to a close, we extend our sincere appreciation to everyone who contributed to this inspiring global gathering.

At this year's event in Dubai, presented an unprecedented integrated showcase—featuring ten major subsidiaries and nearly 50 innovative products and solutions. Highlights included the ™ Intravascular Lithotripsy (IVL) System and ™ Piezoelectric Cornonary Intravascular Ultrasound Therapy System, both coronary-focused innovations that drew strong interest through its well-received hands-on experience. In addition, advanced robotic platforms such as the ™ Multi-port Endoscopic Surgical Robot, Toumai™ Single-port Endoscopic Surgical Robot, and ™ Orthopedic Surgical Robot, along with other cutting-edge technologies, demonstrated the expanding potential of intelligent surgical practice.

Through immersive interaction, we strengthened collaboration with healthcare leaders across the Middle East and showcased our commitment to comprehensive, multidisciplinary care. We are grateful to our partners, medical professionals, and colleagues for your trust, dedication, and shared vision of advancing healthcare innovation.

We look forward to continuing this journey together—and to seeing you again next year.

08/02/2026

At JIM GISE held in Rome, Italy on February 5, 2026, invited Professor Fei Ye and Professor Wei You's team from Nanjing First Hospital to present a complex PCI procedure through a cross-border live case demonstration, earning high recognition from interventional experts worldwide.

Guided by precise intravascular imaging and a standardized treatment pathway, the team addressed the complex lesion using MicroPort's integrated coronary intervention portfolio. Under IVUS guidance, the procedure began with the ™ 1.25 mm Integrated Coronary Rotational Atherectomy System followed by the ™ 3.0 × 12 mm Intravascular Lithotripsy System to effectively modify calcification and optimize vessel compliance. A 3.0 × 33 mm FireHawk™ Sirolimus Targeted Drug Eluting stent was then precisely implanted to achieve full lesion coverage, while the ™ 3.0 × 25 mm Sirolimus Drug Coated Balloon was applied to optimize the side-branch ostium. Post-procedural imaging showed satisfactory vessel patency and coronary flow.

This cross-border live case highlighted the strengths of our total solution for complex coronary lesions and provided valuable insight for the global interventional community. MicroPort also sincerely appreciates the strong support and outstanding professionalism demonstrated by the expert team from Nanjing First Hospital. Moving forward, we will continue to advance innovative coronary technologies to benefit patients worldwide.

04/02/2026

🌍 Something BIG is coming to Dubai…

At WHX Dubai 2026, is set to break barriers:

🔹 10 therapeutic areas
🔹 40+ solutions
🔹 1 unified mission:

From surgical robotics to cardiovascular care, orthopedics to neurovascular and beyond, come experience how we’re redefining the patient journey.

📍 Visit us: Booth N27.E10 | Medical Equipment & Device Hall
📅 Dates: February 9–12, 2026
🏢 Location: Dubai Exhibition Centre (DEC)

👋 Our teams are ready. Come & join us!

MicroPort Cardiovascular | MicroPort NeuroScientific | MicroPort Orthopedics | MicroPort CardioFlow | MicroPort MedBot | MicroPort Endovastec | MicroPort EP | MicroPort Urocare

27/01/2026

underscores a strategic advancement as its coronary product portfolio achieves institutional access and enters routine clinical use at a leading hospital in Macao, China. The portfolio covers key interventional segments including stents, balloons, and CTO accessory, marking an important step in the company's systematic regional expansion and providing valuable clinical reference for the broader Asia-Pacific market.

Products now in clinical application include Firehawk Liberty™ Rapamycin Target Eluting Coronary Stent System, Firesorb™ Bioresorbable Rapamycin Eluting Coronary Scaffold System, Firefighter™ / Firefighter™ NC PTCA Balloon Dilatation Catheter, and Fireflow™ MicroCross™ Microcatheter.

Macao's highly internationalized healthcare system applies rigorous standards to the adoption of interventional devices. Clinical experience generated in this market is expected to provide valuable reference for regional and global practice.

We remain committed to advancing innovative solutions for the management of complex coronary diseases. Building on the successful, system-level clinical adoption of its coronary portfolio in Macao, we will continue to expand clinical collaboration, accelerate regional and global access, and deliver advanced, reliable coronary therapies in support of for patients worldwide.

30/12/2025

proudly announces the first clinical use of the ™ Sirolimus-Coated Coronary Balloon Catheter in Hong Kong, China.

🎯 This meaningful step forward in the regional adoption of our coronary drug-coated balloon therapy for complex calcified coronary lesions was successfully performed at United Christian Hospital by Dr. Dennis Chow Hiu Cheong and Dr. Anthony Wong Siu Fung, further strengthening MicroPort’s comprehensive portfolio in coronary intervention.

The 86-year-old NSTEMI patient with a history of cured colon cancer presented with a severely calcified LAD lesion accompanied with multiple coronary aneurysms. Given the patient’s prior history of per-rectal bleeding during DAPT, drug-coated balloon therapy was considered more appropriate than drug-eluting stent implantation. Following careful procedural planning, lesion preparation was initially performed using rotational atherectomy for the calcified LAD lesion. This was followed by further lesion preparation with cutting balloons and non-compliant balloons, without evidence of vessel recoil. OCT was subsequently used to assess lesion preparation, confirming an adequate lumen area suitable for DCB therapy. Firelimus™ Sirolimus-Coated Coronary Balloon Catheter of 2.5 mm×35 mm and 3.5 mm×35 mm were then deployed to treat the mid-distal and proximal segments of the LAD. Final angiography demonstrated TIMI grade 3 flow, and the procedure was concluded successfully.

✅ The newly launched Firelimus™ Sirolimus-Coated Coronary Balloon Catheter incorporates the patented MicroCrystalute™ coating technology, enabling rapid transfer of pure Sirolimus to the vessel wall with tissue retention over 28 days, while its excipient-free drug coating reduces vascular inflammation hypersensitivity reactions and offers a full-diameter portfolio with 40 mm length options to meet diverse clinical needs.

We value our collaboration with United Christian Hospital and extend our deepest gratitude to Dr. Dennis Chow Hiu Cheong, Dr Anthony Wong Siu Fung and their team for exemplary clinical expertise, masterful skills, and unwavering commitment to patient care. In the future, MicroPort will continue to accelerate the clinical adoption and broad availability of our innovative products, enabling more patients to achieve hashtag .

MicroPort

22/05/2026

18/05/2026

08/05/2026

07/04/2026

27/02/2026

12/02/2026

08/02/2026

04/02/2026

27/01/2026

30/12/2025

Address

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share